YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

In ∼30% of patients with EGFR-mutant lung adenocarcinomas whose disease progresses on EGFR inhibitors, the basis for acquired resistance remains unclear. We have integrated transposon mutagenesis screening in an EGFR-mutant cell line and clinical genomic sequencing in cases of acquired resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Pang-Dian, Narzisi, Giuseppe, Jayaprakash, Anitha D., Venturini, Elisa, Robine, Nicolas, Smibert, Peter, Germer, Soren, Yu, Helena A., Jordan, Emmet J., Paik, Paul K., Janjigian, Yelena Y., Chaft, Jamie E., Wang, Lu, Jungbluth, Achim A., Middha, Sumit, Spraggon, Lee, Qiao, Huan, Lovly, Christine M., Kris, Mark G., Riely, Gregory J., Politi, Katerina, Varmus, Harold, Ladanyi, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2018
Materias:
PNAS Plus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042104/
https://www.ncbi.nlm.nih.gov/pubmed/29875142
http://dx.doi.org/10.1073/pnas.1717782115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042104/
https://www.ncbi.nlm.nih.gov/pubmed/29875142
http://dx.doi.org/10.1073/pnas.1717782115

Ejemplares similares